University of Virginia appoints Mitchell Rosner, M.D., as Chief Executive Officer for the health system
UVA Health Appoints Dr. Mitchell Rosner as Permanent CEO
Dr. Mitchell Rosner, a long-standing faculty member at the University of Virginia (UVA) School of Medicine, has been appointed as the permanent CEO of UVA Health for a term of three years.
Rosner, who joined the School of Medicine faculty 21 years ago, has been serving as the interim leader of the health system since July last year. The appointment follows seven months after Jim Ryan, the former UVA President, asked Rosner to take on the interim role.
Before his interim and permanent appointments as CEO, Rosner had not served in the position before. His predecessor, Dr. K. Craig Kent, resigned as the CEO in February.
The appointment of Rosner as CEO of UVA Health marks the first time he has held the position as a permanent leader. Prior to his appointment, he had been a dedicated faculty member at the School of Medicine.
The previous CEO, Dr. Melinda A. Merrell, held the position before Kent. The appointment of Rosner as CEO of UVA Health was made by the school's administration.
Jim Ryan, the former UVA President, had initially asked Rosner to serve as the interim leader of the health system seven months ago. The appointment comes after Rosner's successful stint as the interim leader for seven months.
UVA Health is one of the leading academic medical centers in the United States, and with Rosner at the helm, it is poised to continue its mission of providing world-class patient care, education, and research.
Rosner's appointment as CEO of UVA Health is a testament to his dedication, expertise, and commitment to the institution. As he takes on this new role, the UVA community looks forward to seeing the positive impact he will have on the health system.
Read also:
- Guide to Effective Utilization: Advanced Practice Providers - A Comprehensive Video Tutorial
- Conventional Medicine's Domain Shrinks as Complementary and Alternative Therapies Gain Popularity
- Restoring SCN2A gene function in mice through CRISPR activation enhances neurodevelopmental outcomes.
- New York joins a multistate health coalition to counteract chaos in federal vaccine distribution efforts
